Category Archives: Dermatology

Dermatology

Global Surgical Cameras Market to Reach $7 Billion by 2030 – Yahoo Finance

ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, April 26, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Surgical Cameras Industry" - https://www.reportlinker.com/p06033044/?utm_source=GNW Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and Chinas already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Surgical Cameras Market to Reach $7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Surgical Cameras estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$7 Billion by 2030, growing at aCAGR of 12.3% over the period 2022-2030. HD & Full HD, one of the segments analyzed in the report, is projected to record 13.4% CAGR and reach US$4.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the SD segment is readjusted to a revised 10.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $754.6 Million, While China is Forecast to Grow at 18.4% CAGR

The Surgical Cameras market in the U.S. is estimated at US$754.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 10.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8% CAGR.

Select Competitors (Total 42 Featured)- Allied Vision Technologies GmbH- Canon Inc- Carl Zeiss AG- Leica Microsystems- Olympus Corporation- Richard Wolf GmbH- Sensor Technologies America, Inc- Smith & Nephew PLC- Sony Corporation- Videology Imaging Solutions, Inc;

Read the full report: https://www.reportlinker.com/p06033044/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEWInfluencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global RecessionSurgical Cameras - Global Key Competitors Percentage MarketShare in 2022 (E)Competitive Market Presence - Strong/Active/Niche/Trivial forPlayers Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis forSurgical Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Surgical Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Surgical Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for SD byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2022 through 2030 and % CAGR

Table 5: World Historic Review for SD by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for SD by Geographic Region -Percentage Breakdown of Value Sales for USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for HD &Full HD by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for HD & Full HD by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 9: World 16-Year Perspective for HD & Full HD byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis forUltra HD by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Ultra HD by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 12: World 16-Year Perspective for Ultra HD by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis forClinics & Dental Chambers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Clinics & Dental Chambersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Clinics & DentalChambers by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2014, 2023 &2030

Table 16: World Recent Past, Current & Future Analysis forOther End-Uses by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Other End-Uses byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Other End-Uses byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis forHospitals by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Hospitals by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR

Table 21: World 16-Year Perspective for Hospitals by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis forEndoscopy Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Endoscopy Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Endoscopy Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis forMicrosurgery Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Microsurgery Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Microsurgery Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis forDermatology Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Dermatology Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Dermatology Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis forOphthalmology Cameras by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 32: World Historic Review for Ophthalmology Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 33: World 16-Year Perspective for Ophthalmology Camerasby Geographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 34: World Recent Past, Current & Future Analysis forDental Cameras by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR

Table 35: World Historic Review for Dental Cameras byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 36: World 16-Year Perspective for Dental Cameras byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030

Table 37: World Surgical Cameras Market Analysis of AnnualSales in US$ Million for Years 2014 through 2030

Table 38: World Recent Past, Current & Future Analysis forAmbulatory Surgery Centers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Million for Years 2022 through 2030 and % CAGR

Table 39: World Historic Review for Ambulatory Surgery Centersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 40: World 16-Year Perspective for Ambulatory SurgeryCenters by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2014, 2023 &2030

III. MARKET ANALYSIS

UNITED STATESSurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in the United States for 2023 (E)Table 41: USA Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 42: USA Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 43: USA 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 44: USA Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 46: USA 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 47: USA Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 48: USA Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 49: USA 16-Year Perspective for Surgical Cameras by Type -Percentage Breakdown of Value Sales for Endoscopy Cameras,Microsurgery Cameras, Dermatology Cameras, OphthalmologyCameras and Dental Cameras for the Years 2014, 2023 & 2030

CANADATable 50: Canada Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 51: Canada Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 52: Canada 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 53: Canada Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 54: Canada Historic Review for Surgical Cameras byEnd-Use - Clinics & Dental Chambers, Ambulatory SurgeryCenters, Other End-Uses and Hospitals Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 55: Canada 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 56: Canada Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 57: Canada Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 58: Canada 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

JAPANSurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Japan for 2023 (E)Table 59: Japan Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 60: Japan Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 61: Japan 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 62: Japan Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 63: Japan Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Japan 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 65: Japan Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 66: Japan Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 67: Japan 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

CHINASurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in China for 2023 (E)Table 68: China Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 69: China Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 70: China 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 71: China Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 72: China Historic Review for Surgical Cameras by End-Use -Clinics & Dental Chambers, Ambulatory Surgery Centers, OtherEnd-Uses and Hospitals Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 73: China 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Table 74: China Recent Past, Current & Future Analysis forSurgical Cameras by Type - Endoscopy Cameras, MicrosurgeryCameras, Dermatology Cameras, Ophthalmology Cameras and DentalCameras - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 75: China Historic Review for Surgical Cameras by Type -Endoscopy Cameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 76: China 16-Year Perspective for Surgical Cameras byType - Percentage Breakdown of Value Sales for EndoscopyCameras, Microsurgery Cameras, Dermatology Cameras,Ophthalmology Cameras and Dental Cameras for the Years 2014,2023 & 2030

EUROPESurgical Cameras Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Europe for 2023 (E)Table 77: Europe Recent Past, Current & Future Analysis forSurgical Cameras by Geographic Region - France, Germany, Italy,UK, Spain, Russia and Rest of Europe Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2022 through2030 and % CAGR

Table 78: Europe Historic Review for Surgical Cameras byGeographic Region - France, Germany, Italy, UK, Spain, Russiaand Rest of Europe Markets - Independent Analysis of AnnualSales in US$ Million for Years 2014 through 2021 and % CAGR

Table 79: Europe 16-Year Perspective for Surgical Cameras byGeographic Region - Percentage Breakdown of Value Sales forFrance, Germany, Italy, UK, Spain, Russia and Rest of EuropeMarkets for Years 2014, 2023 & 2030

Table 80: Europe Recent Past, Current & Future Analysis forSurgical Cameras by Resolution Type - HD & Full HD, SD andUltra HD - Independent Analysis of Annual Sales in US$ Millionfor the Years 2022 through 2030 and % CAGR

Table 81: Europe Historic Review for Surgical Cameras byResolution Type - HD & Full HD, SD and Ultra HD Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR

Table 82: Europe 16-Year Perspective for Surgical Cameras byResolution Type - Percentage Breakdown of Value Sales for HD &Full HD, SD and Ultra HD for the Years 2014, 2023 & 2030

Table 83: Europe Recent Past, Current & Future Analysis forSurgical Cameras by End-Use - Clinics & Dental Chambers,Ambulatory Surgery Centers, Other End-Uses and Hospitals -Independent Analysis of Annual Sales in US$ Million for theYears 2022 through 2030 and % CAGR

Table 84: Europe Historic Review for Surgical Cameras byEnd-Use - Clinics & Dental Chambers, Ambulatory SurgeryCenters, Other End-Uses and Hospitals Markets - IndependentAnalysis of Annual Sales in US$ Million for Years 2014 through2021 and % CAGR

Table 85: Europe 16-Year Perspective for Surgical Cameras byEnd-Use - Percentage Breakdown of Value Sales for Clinics &Dental Chambers, Ambulatory Surgery Centers, Other End-Uses andHospitals for the Years 2014, 2023 & 2030

Read the original here:

Global Surgical Cameras Market to Reach $7 Billion by 2030 - Yahoo Finance

Dermatology

Aesthetic Dermatology Market Expected to Growth 10.2% by 2029: Key Insights, Growth Strategies, Top Companies – openPR

Global Aesthetic Dermatology Market

The primary objective of the report is to educate business owners and assist them in making an astute investment in the market. The study highlights regional and sub-regional insights with corresponding factual and statistical analysis. The report includes first-hand, the latest data, which is obtained from the company website, annual reports, industry-recommended journals, and paid resources. The Aesthetic Dermatology market report will facilitate business owners comprehending the current trend of the market and making profitable decisions.

Grab Sample Report with Complete Graphs, Charts and Figures @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-aesthetic-dermatology-market

Aesthetic dermatology works to heal skin and hair concerns in a way that they appear healthier, even going as far as boosting self-confidence of patients who have been unhappy with the way they look. Aesthetic dermatology has grown to become an important issue in the field of dermatology. Aesthetic dermatology puts medicine in a field of tension between medical necessities and patients' wishes. Aesthetic issues are mostly relevant to dermatology because skin is not only a functional organ like heart, liver and kidneys, but a medium also of visual and tactile communication. The desire for beauty and youth is thus often expressed by patients seeking advice on the improvement of their appearance and looks.

Who Are the Global Aesthetic Dermatology Market Leading Players?

AbbVie Inc. (U.S.)Henry Schein(U.S.)Merz Pharma (Germany)Cutera (U.S.)Inc. (A Subsidiary of HologicInc.) (U.S.)Candela Medical (U.S.)Bausch Health Companies Inc. (Canada)(U.S.)Medytox (South Korea)LUTRONIC (South Korea)(South Korea)En. S.p.A. (Italy)Hoahai Biological Technology (China)REVANCE THERAPEUTICS (U.S.)Lumenis Be Ltd. (Israel)Venus Concept (Canada)Alma Lasers (Israel)Fotona (Slovenia)Aesthetic Biomedical (U.S.)(U.S.)R2 TECHNOLOGIES(A Subsidiary of INNOVATE Corp.) (U.S.)Sensus Healthcare(U.S.)Aesthetic Technology Limited (U.K.)DELEO (France)Biotech Italia Srl (France)Medency (Italy)Aerolase Corp. (U.S.)Sciton (U.S.)Image Derm(U.S.) and PhotoMedex (U.S.)

Access 350 Page Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-aesthetic-dermatology-market

Aesthetic Dermatology Segmentation Analysis:

Product Type

MedicinesDevices

Surgery Type

Minimally InvasiveNon-Invasive

Treatment Type

Face TreatmentBody Treatment

Application

Skin RejuvenationSkin ResurfacingSkin TighteningHair RemovalPigmented & Vascular LesionsTattoo RemovalScarAcneDyschromiaSkin TagsPsoriasisWartsHyperhidrosisMoles And FrecklesOthers

Gender

FemaleMale

End User

HospitalsDermatology ClinicsSurgical CentresSpa ClinicsOthers

Distribution Channel

Direct TenderRetail Sales

Browse Detailed Summary of Research Report @ https://www.databridgemarketresearch.com/reports/global-aesthetic-dermatology-market

By Regions

-> North America

-> Europe

-> Japan

-> Porcelain

-> Southeast Asia

-> India

-> Korea

-> MEA

The current market dossier provides market growth potential, opportunities, industry drivers, and challenges, and market share risks along with the growth rate of the global Aesthetic Dermatology market. The report also covers currency and exchange rate fluctuations, import and export trade, and the global market.

The global Aesthetic Dermatology market and Aesthetic Dermatology market size are segmented by player and region (country), type, and application. Players, stakeholders, and other participants in the global Aesthetic Dermatology market will be able to gain the upper hand by using the report as a powerful resource. Segment analysis focuses on revenue and forecasts by type and application for the period 2022-2029. Furthermore, the Aesthetic Dermatology industry report helps up-and-coming companies make a positive assessment of their business plans as it covers a variety of topics that market players need to consider in order to remain competitive.

Aesthetic Dermatology Market Segmentation and Competitive Analysis: Apart from an overview of successful marketing strategies, market contributions and current developments of leading companies, the report also offers a dashboard with overview information on past and current performance of leading companies. The research report uses different methodologies and analysis to provide in-depth and accurate information about the Aesthetic Dermatology market.

This Aesthetic Dermatology Market Research/Analysis Report Will Provide Answers to Your Upcoming Questions

Q1. What manufacturing technology is used for Aesthetic Dermatology? What's new in this technology? What trends are causing these developments? Who are the major global players in this Aesthetic Dermatology market?

Q2. What is your company profile, product information and contact information? What Was Global Market Status of the Aesthetic Dermatology Market? What Was Capacity, Production Value, Cost and PROFIT of Aesthetic Dermatology Market? What is the current market status of the Aesthetic Dermatology industry? How is the competition in the market for this industry, both by company and by country?

Q3. What is Market Analysis of the Aesthetic Dermatology Market Considering Applications and Types?

Q4. What are the forecasts for the global Aesthetic Dermatology industry, taking into account capacity, production and production value? What will be the cost-benefit estimate? What will be the market share, supply and consumption? What about imports and exports? What Is Aesthetic Dermatology Market Chain Analysis by Upstream Raw Materials and Downstream Industries?

Q5. What Is the Economic Impact On The Aesthetic Dermatology Industry? What are the results of the analysis of the global macroeconomic environment? What are the development trends of the global macroeconomic environment? What are the market dynamics of the Aesthetic Dermatology Market? What are the challenges and opportunities?

Q6. What Should Be Entry Strategies, Countermeasures to Economic Impact, And Marketing Channels for Aesthetic Dermatology Industry?

Table of Contents:

Part 01: Executive SummaryPart 02: scope of the reportPart 03: research methodologyPart 04: IntroductionPart 05: Aesthetic Dermatology Market OverviewPart 06: Aesthetic Dermatology Market SizePart 07: Five Forces AnalysisPart 08: Aesthetic Dermatology Market Segmentation by TechnologyPart 09: Aesthetic Dermatology Market Segmentation by ApplicationPart 10: Customer LandscapePart 11: Aesthetic Dermatology Market Segmentation by End UserPart 12: regional landscapePart 13: decision frameworkPart 14: Drivers and ChallengesPart 15: Aesthetic Dermatology Market TrendsPart 16: Competitive LandscapePart 17: company profilesPart 18: Appendix

To Check the Complete Table of Contents, Click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-aesthetic-dermatology-market

Databridgemarketresearch.com always strives to provide high-quality products, believing that quality is the soul of business. Through years of efforts and the support of a large number of customer services, Databridgemarketresearch.com advisory group has accumulated creative design methods in many high-quality market research and a research team with rich experience.

View Most Popular Reports by Databridgemarketresearch.com Here:

Browse Related Reports:

https://social.kubo.chat/read-blog/9630

https://baitk.com/read-blog/11854

https://bib.az/read-blog/31472

https://wignar.com/read-blog/15521

https://yruz.one/blogs/26041/Asia-Pacific-Stem-Cell-Therapy-Market-Size-2023-Share-Growth

https://moniispace.com/read-blog/28198

https://omiyou.com/read-blog/29980

https://famenest.com/read-blog/32499

https://ubiz.chat/read-blog/35586

https://geto.space/read-blog/107243

https://uchatoo.com/read-blog/11860

https://social.kubo.chat/read-blog/9633

https://baitk.com/read-blog/11856

https://bib.az/read-blog/31476

https://wignar.com/read-blog/15522

https://yruz.one/blogs/26051/Middle-East-Africa-Stem-Cell-Therapy-Market-Size-Business-Statistics

https://moniispace.com/read-blog/28199

https://omiyou.com/read-blog/29982

https://famenest.com/read-blog/32501

https://ubiz.chat/read-blog/35589

https://geto.space/read-blog/107247

https://uchatoo.com/read-blog/11863

https://social.kubo.chat/read-blog/9636

https://baitk.com/read-blog/11859

https://bib.az/read-blog/31479

https://wignar.com/read-blog/15524

https://yruz.one/blogs/26059/North-America-Stem-Cell-Therapy-Market-Size-Share-Growth-Trend

https://moniispace.com/read-blog/28204

https://omiyou.com/read-blog/29986

https://famenest.com/read-blog/32505

https://ubiz.chat/read-blog/35591

https://geto.space/read-blog/107252

https://uchatoo.com/read-blog/11866

https://social.kubo.chat/create-blog/

https://baitk.com/read-blog/11865

https://bib.az/read-blog/31484

https://wignar.com/read-blog/15528

https://yruz.one/blogs/26067/Age-Related-Macular-Degeneration-AMD-Market-Product-Types-Competitive-Landscape

https://moniispace.com/read-blog/28210

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475E-Mail: Corporatsesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than

5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

Originally posted here:

Aesthetic Dermatology Market Expected to Growth 10.2% by 2029: Key Insights, Growth Strategies, Top Companies - openPR

Dermatology

How, where to get medical records from closed Myrtle Beach dermatology office – wpde.com

MYRTLE BEACH, S.C. (WPDE)

Thousands of local dermatology patients are one step closer to getting their medical records back after Dermatology and Skin Cancer Center SC closed without warning in February.

It has now been more than 40 days that patients haven't been able to access their records, and many of these patients have cancer.

ABC15 first broke the story afterseveral patients reached out to us to investigate the unexpected closure.

READ MORE: Patients say MB dermatology office closes, fails to disclose medical records, requests

The office abruptly closed without warning to either employees, and patients, on February 17, and never reopened.

Initially, ABC15reached out to the South Carolina Department of Labor Licensing and Regulationin March to askhow patients could get their records back.

Now, alongside the state Board of Medical Examiners, they have officially enacted a petition appointing another doctor as the custodian for these records.

Dermatology and Skin Cancer Center SC Myrtle Beach office (Credit: Emma Parkhouse/WPDE)

Here's how to do it.

The Board confirmed the associated medical offices were closed down after a transfer of ownership fell through.

The initial owner, Dr. Joseph Masessa, died in 2019.

His practice was taken over by his brother, Jeffery Masessa, who is not a licensed physician in South Carolina.

According to the Board, Jeffery never reached out to the state's labor department or the Board about the closure; or made any arrangements for record retrieval.

SUGGESTED: Patients can retrieve records after Myrtle Beach dermatology office unexpectedly closed

The board determined while Jeffery Masessa may have once been considered a "responsible party at one point in time", he no longer is.

In addition, because Dr. Joseph Masessa is deceased, the Board has the legal authority to appoint a custodian of the records.

Board-certified surgeon and dermatologist, Dr. Brandon Coakley at Waccamaw Dermatology has been selected as that custodian.

"Patients have been panicked. There's patients that went into the doctor's office and were told, 'hey, you have a spot that's suspicious for cancer'; a biopsy was taken, and then there was no answer," said Coakley.

Waccamaw Dermatology office in Myrtle Beach (Credit: Emma Parkhouse/WPDE)

Dr. Coakley told ABC15 according to the closed office's former manager,Dermatology and Skin Cancer Center SC in Myrtle Beach had roughly 36,000 patient visits in 2022.

Even if those patients attended the office multiple times throughout the year, Coakley says there will be at least 10,000 patients impacted by this.

He's still waiting to hear back about a confirmed number of patient files.

While he's not sure exactly how many thousands of records there are at the moment, Dr. Coakley is sure that he wants to help these patients in anyway he can.

"We will be contacting, as per the medical board's order, contacting every patient to let them know that we have the records," said Coakley. "I don't know the state of the paper records. My plan is to contact everybody who had an email on file electronically because that's faster and easier, but we will go through the process of organizing the paper records and notifying those people by regular first class mail."

Dr. Coakley and his office staff at Waccamaw Dermatology will be receiving all of the paper and digital records from Dermatology and Skin Cancer Center SC over the next couple of days.

Waccamaw Dermatology andDermatology and Skin Cancer Center SC are not associated or affiliated with each other.

NEW: Trump surrenders at Manhattan courthouse ahead of arraignment in hush money case

ABC15 got ahold of Jeffery Masessa Tuesday afternoon.

Over the phone, our reporter asked him if he was available for an interview to talk about the closing of the dermatology offices he owns in South Carolina.

He agreed to an interview and said he would call back after a meeting to set it up. Since then, he has not returned any phone calls or texts.

The Board and the state LLR have stated they have still not heard from, or been able to get in contact, with Jeffery Masessa.

Dr. Coakley says he and his team will be working as quickly as possible to obtain and organize the records as they prepare to directly contact everyone whose been affected.

Updates on obtaining medical records for former patients ofDermatology and Skin Cancer Center SC will be posted here.

His office is located at 5046 Highway 17 Bypass South, in Suite 200.

This is a developing story. Stay with ABC15 News for updates.

Original post:

How, where to get medical records from closed Myrtle Beach dermatology office - wpde.com

Dermatology

Dermatology Month in Review: Highlights from March 2023 – MD Magazine

This past month on HCPLive, several important topics were covered as part of our dermatology content from March.

The list includes new trial data on psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and prurigo nodularis (PN) treatment options.

The following list is a summary of these major breakthroughs covered in March in the dermatology space, with more news and updated content on these topics available on the HCPLive main news page.

1. Positive Phase 3 Trial Results for Tapinarof Cream on Atopic Dermatitis

In this HCPLive article, phase 3 data from the ADORING 2 trial indicated that about of half of AD patients treated with tapinarof, 1% showed improvement on the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM).

The investigators noted that tapinarof may be potential two-in-one first-line topical treatment for both atopic dermatitis and plaque psoriasis, as the new trial found the cream to be both safe and tolerable for all age groups down to 2 years.

The study results were announced by biopharmaceutical company Dermavant Sciences.

2. Positive Trial Results for Hand, Foot Eczema Patients Treated with Dupilumab

This late-breaking data was shown at the American Academy of Dermatology (AAD) 2023 conference, showing that about 40% of uncontrolled moderate-to-severe hand and foot AD patients achieved clear or almost clear skin compared to 17% with placebo.

The researchers saw improvements as early as 1 week, noting that there were substantial improvements in measures of sleep, skin pain, as well as hand eczema-related life quality. They noted that the drug was the first biologic evaluated for this particular patient population.

The data was presented by Eric Simpson, MD, the studys principal trial investigator.

3. Nemolizumab Treatment Led to Improved Skin Lesions, Itch for Prurigo Nodularis Patients

Phase 3 data from the OLYMPIA 2 trial, presented at AAD, showed that nemolizumab monotherapy improved skin lesions, itch, and sleep disturbances in adults with moderate-to-severe prurigo nodularis (PN).

The investigators reported that nemolizumab, a first-in-class, interleukin-31 receptor alpha antagonist, met all of the studys primary and key secondary endpoints.

The late-breaking results were presented by Shawn Kwatra, MD, from Johns Hopkins University School of Medicine.

4. Once Daily Roflumilast Improved Symptoms of Atopic Dermatitis in Phase 3 Trials

This late-breaking data, presented at AAD, showed that roflumilast 0.15% once-daily improved AD across multiple efficacy endpoints and produced favorable safety and tolerability in patients.

The results showed that adverse events (AEs) were reported in less than 3.5% of patients, and application site pain incidence was low. The data resulted from the INTEGUMENT-1 and INTEGUMENT-2 studies.

The results were presented by Lawrence Eichenfield, MD, from Rady Children's Hospital.

5. Phase 3 Trial Data on Bimekizumab for Patients with Hidradenitis Suppurativa

This data, also presented at AAD, indicated that a greater percentage of HS patients achieved HiSCR50 for those treated with bimekizumab compared to placebo at week 16 of the study.

The results came from the BE HEARD I and II trials investigating the selective inhibition of IL-17F and IL-17A by bimekizumb, a monoclonal IgG1 antibody.

The research was presented at the conference by lead investigator Alexa B. Kimball, MD, from Beth Israel Deaconess Medical Center.

6. Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks

In this study, oral roflumilast treatment was found to lead to significant Psoriasis Area and Severity Index (PASI) score, with 34.8% of their treatment group reached PASI75 compared to 0.0% in given placebo by week 12.

The late-breaking data on oral roflumilast, a targeted phosphodiesterase (PDE)-4 inhibitor, was presented at AAD 2023. The research team also stated that roflumilast may become a cheap alternative treatment to other psoriasis drugs with more research.

The findings were presented by Alexander Egeberg, MD, PhD, from the University of Copenhagen and Bispebjerg Hospital.

7. Oral TYK2 Inhibitor Led to Significant Skin Clearance Improvement in Psoriasis

These results showed that treatment with TAK-279 (formerly NDI-034858), an oral tyrosine kinase 2 (TYK2) inhibitor, led to significant skin clearance improvement for moderate-to-severe psoriasis patients compared to placebo, especially at a once-daily, 5 mg dose.

The phase 2b clinical trial data was shown at AAD, and the investigators demonstrated that at the highest dose of TAK-279, 33% of study participants reached complete skin clearance by week 12.

The data was presented at the conference by April W. Armstrong, MD, MPH, from USCs Keck School of Medicine.

Read this article:

Dermatology Month in Review: Highlights from March 2023 - MD Magazine

Dermatology

Pure Dermatology will bring skin care, treatments to South Austin – Community Impact Newspaper

Pure Dermatology is coming in May to South Austin and promises to bring skin checks, treatments and more at 8701 Hwy. 71, Ste. 101, Austin.

Opening day will be May 16, said co-owner Dr. Christopher Chu. His wife, Dr. Chelsey Straight, will also be a partner in the dermatology practice. Both are board-certified dermatologists. Chu is also a board-certified dermatopathologist, while Straight is also a board-certified micrographic surgeon.

Services provided will include skin checks, skin cancer treatments including surgical excision and micrographic surgery, treatment of common skin conditions such as acne, rosacea, eczema, psoriasis, warts, etc., hair loss consultations and treatments, and cosmetic treatments including Botox/Dysport, injectable fillers and chemical peels.

For more information, call 512-766-2610 or visit http://www.puredermtx.com in May.

More:

Pure Dermatology will bring skin care, treatments to South Austin - Community Impact Newspaper

Dermatology

Fatty Liver More Frequent in Alopecia Universalis and Patchy … – Dermatology Times

Nadya Kolobova/AdobeStock

A recent study published in the Journal of Cosmetic Dermatology examined the frequency of fatty liver in patients with alopecia areata subtypes, including alopecia universalis (AU) and patchy alopecia areata (PAA).1 After reviewing data from patients with AU and PAA referred to a dermatology clinic from September 23, 2019, to September 23, 2020, study investigators determined that fatty liver was more frequent in patients with AU and PAA compared to a control group, but without statistically significant differences.

Patients without hair loss disorders who attended the same clinic were selected as the control group. Additionally, patients with known liver diseases were excluded from the case-control study. The study investigators began collecting data from the AU and PAA patient groups, including age, sex, weight, and waist circumference. Disease duration and the Severity of Alopecia Tool (SALT) score were also documented among the AU and PAA patient groups.

Overall, 32 patients were included in each study group: AU, PAA, and control. Age, sex, weight, height, BMI, and waist circumference were comparable across all 3 groups. The study investigators found that the frequency of hyperlipidemia was the highest in AU patients (31.3%), followed by PAA patients (15.6%), but the difference was not statistically significant among the groups (p=0.131). Abnormal liver enzymes were recorded in 9.4% of AU patients, 12.5% of PAA patients, and 3.1% of controls (p=0.524). Statin use was also the highest in AU patients (28.1%), with no statistically significant difference among the 3 groups. Finally, disease duration and SALT score were significantly higher in the AU patient group than in the PAA patient group (p=0.009 andp<0.001, respectively).

The study investigators noted that The higher frequency of fatty liver in AU patients compared with the PAA group can be attributed to the longer disease duration and the higher SALT score in this group. To the best of our knowledge, in previous studies, fatty liver has not been evaluated in patients with AA. Still, recently the replacement of nonalcoholic fatty liver disease (NAFLD) with metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed, highlighting the association between fatty liver and metabolic syndrome.

The investigators also noted that the higher frequency of fatty liver in AA patients may be related to an oxidant/antioxidant imbalance, which was reported in the studys patients. Overall, the study suggests that there may be an association between fatty liver and the AU subtype, but larger studies are needed to confirm the correlation.

Reference

Read more from the original source:

Fatty Liver More Frequent in Alopecia Universalis and Patchy ... - Dermatology Times

Dermatology

Dermatologist Jessie Cheung on How to Make Your Penis Bigger – Men’s Health

NO SURPRISE TO anyone whos been living on planet Earth, but a lot of men want to have a bigger penis. The thing is, we cant go to the gym, do three sets of dumbbell penis reps, and get a larger schlong. If it were that easy, nearly every guy would be walking around with a snake in his pants.

Still, there actually are some things you can do to get a bigger penis, but many of these procedures are not cheap and come with some serious health risks. Nevertheless, we know you're probably curious about the wild world of penis enlargement, which is why we reached out to Jessie Cheung, M.D., a board-certified dermatologist who specializes in some of these techniques. Cheung has been a dermatologist for nearly 20 years, and six years ago, she moved from doing medical dermatology to focusing exclusively on cosmetic and sexual dermatology.

In addition to standard facial cosmetic procedures, Cheungwho's based in Manhattan and Chicagoperforms a slew of penis procedures, including fillers, fat injections, Bocox (that's Botox for your cock, FYI), and Emsella (a form of electromagnetic therapy that helps with premature ejaculation and erection strength.)

We interviewed Cheung about her dermatological methods for making patients' penises bigger, longer, and even capable of lasting longer during sex.

This interview has been lightly edited and condensed for clarity.

I dont want to brag, but a lot, hundreds. As a dermatologist, I'm used to looking at skin everywhere, including the penis, anus, scrotum, and perineum, and dealing with warts, hemorrhoids, and fissures. I stopped doing medical dermatology years ago and now focus on cosmetics, hormones, and sexual health. So that brings in men who need help with their erectile function, libido, premature ejaculation, and men who have purely cosmetic issues. The big one, of course, is increasing their penis size.

Actually, I see more men who complain about erectile dysfunction instead of size, but they always say that even if they are happy with their size, they wouldn't mind more length or girth.

I give them statistics: Numbers are facts. Interestingly, many of my men who want bigger penises have above-average length and girth. I think porn makes them lose touch with reality, just like we're seeing social media distort our perception of beauty.

Penis length must be 2.5 standard deviations below the average for that age to be considered a micropenis. For adults, that is 9.3 cm when stretched or 3.6 inches. In my office, I consider it a micropenis if they are too short to penetrate their partner.

Not that often. I would say my whole career, probably two that were so small they couldn't penetrateand that's really short. When its that small, they may want surgical intervention, and I dont do penis surgeries. So because of that, I don't see many men with a proper micropenis.

Yeah, so I perform filler injections. I also perform P-shots, which are designed to treat ED but have the additional benefit of increasing size, specifically girth. P-shots involve injecting biological substances such as Platelet-rich plasma (PRP). PRP is a source of growth factors for blood vessels and tissue, so activating the hibernating stem cells in the arteries and nerves stimulates repair and the production of healthy tissue.

P-shots start at $1800 and increase depending on the protocol used.

Ill try not to be too technical, but we draw your blood in these special tubes. We spin it down on the centrifuge, and on the top coat, there's a layer that's kinda yellowy, that's very rich with platelets, which contains eight to ten growth factors that are good for your blood vessels, collagen, and stem cell activation. So we inject that into places where you want to turn on stem cells, whether into your scalp to grow hair, your skin to help with wound healing, or the penis to activate stem cells to make blood vessels and nerves again. That said, PRP is about 10 to 15 years old. I prefer to use exomes.

So, I perform a topical infusion of exosomes, which really is the cutting edge of regenerative medicine. Exosomes are basically little email packets of information that your stem cells secrete to turn each other on and talk to each other. And they're filled with RNA, proteins, and peptides. Exomes have hundreds of more growth factors than PRP. They're also anti-inflammatory. So I use exosomes the exact same way I use P-shots, to help with ED, functionality, and size.

Anti-inflammation helps prevent tissue from aging. So in the case of penises, this will help you retain your functionality and erection strength as you age.

Fat is a great filler, and since fat is full of stem cells, I recommend fat for improving size and restoring erectile function. You will see increased girth and can regain lost length, both flaccid and erect.

A fat transfer to the penis is very straightforward. The injection technique is similar to how we inject the penis with regular fillers, but we are harvesting your own fat with gentle liposuction and processing the fat with PRP or exomes. I like to take fat from the pubic mound, which helps to expose more of the base of the penis to create more visible length. I call it pulling the turtle out of the shell.

Fat is a very cost-effective filler, and since fat functions as a natural implant, it lasts much longer than other fillers. The most significant benefit of using fat is the improvement of functionality, as the wound-healing activation of stem cells will target nerves and blood vessels to improve sensitivity and circulation. I like to transfer at least 20 mL of fat, which starts at $8,000.

There are risks associated with any injection! But understanding the anatomy and potential complications will mitigate those risks. For example, you don't want any material getting into large arteries, which can cause tissue to die. You also have to respect the layers and boundaries of the penis to avoid migration of the filler (i.e., the filler all moving to one place and sitting there). Bruising, swelling, uneven appearance, and infection are potential complications that I warn my patients about.

No, I have never had a patient who asked for a smaller penis. But penises do shrink over time, as testosterone levels fall and there is a decrease in blood flow. The blood vessels and tissue scar down and get stiff, so they can't stretch and fill up with blood for a full erection. As a result, men will notice their penis looking smaller while flaccid and erect and report softer erections.

Typically men in their fifties and sixties, though Ive seen men coming and seeking help for their shrinkage in their thirties.

Staying healthy [and] keeping your hormone levels optimized. [And you do that by] having a good quality of sleep, a healthy diet, keeping stress levels low, and not smoking. So things that are generally thought of as bad for you will negatively affect your penis size as you age.

Yes, my patients love Bocox! It helps with size and erections. Botulinum toxin works by relaxing the smooth muscle in the blood vessels of the penis. This means the blood vessels are more dilated and filled with blood at rest, so the penis hangs longer and thicker when flaccid. So its great if youre a grower and not a shower. But even with an erection, the penis is even more full of blood than usual, so it is harder and may be thicker. Bocox is a relatively safe treatment. It's usually two pokes after the application of a topical numbing cream. Risks include mild bruising and swelling.

So it's electromagnetic therapy. Basically, you're sitting on a chair, and a powerful magnet is at the chair's base. That magnet makes your pelvic floor muscles activate. So essentially, you're doing kegel exercises, whether it be for the penis, the vagina, or the anus. For the penis, that can help with premature ejaculation, but also erection strength and even size because of the increased blood flow. We have men who do Emsella for the anus, specifically sphincter control. There's a statistic that you complete over 11,000 Kegel exercises in 28 minutes on the Emsella chair. So it's very legit, and I love using it on my patients.

I will refuse to treat a patient who has unrealistic expectations. Beyond that, everyone has their own desired aesthetic, so I won't judge a man if he wants to have a huge penis. To each their own!

Social media and porn have created unrealistic expectations for bodies, faces, and genitalia. It's difficult to maintain a smooth, pink anus or vagina or penis or even nipples as we age, and sexual confidence is at an all-time low. Sex is excellent for your physical and mental health and appearance, so a therapeutic procedure that encourages sexual wellness and confidence is not really up to public judgment. It's a private health issue.

I had a patient who had filler injections done elsewhere. He had 15 syringes done in one session, and all the filler clumped up at the head of his penis. It was this huge blob. It looked like a golf ball.

So he came after it was botched to get it fixed. But didnt want to get the filler removed. So what I did was add more filler at the shaft and base, essentially to blend it in better.

Aside from the usual wows, what's memorable are the stories I hear when my patients return: sex multiple times a day, getting propositioned on Snapchat, video parties, and underground fame. My patients are definitely more confident. I had one patient who was too short to penetrate his partner, and after a combination of hormones, a P-shot, and fat transfer, he was finally able to have penetrative sex!

Go here to see the original:

Dermatologist Jessie Cheung on How to Make Your Penis Bigger - Men's Health

Dermatology

Dr. Arvinder Singh Awarded As Father Of Cosmetic Dermatology In The International Fame Award – Zee News

Dr. Arvinder Singh has been bestowed with the prestigious International Fame Award by the famous Bollywood Actress Shilpa Shetty Kundra. He has been awarded as Father of Cosmetic Dermatology for his contribution to the field of Cosmetic Dermatology, Clinical Cosmetology, Medical Aesthetics, and Medical LASERS.

COMMERCIAL BREAK

SCROLL TO CONTINUE READING

As the CEO and MD of the Arth Group of Companies and a cosmetic dermatologist who holds the world record in this field, Dr. Arvinder Singh is well-known for his expertise in chemical peels, botox, and dermal fillers. He is a Rajasthan-based, internationally board-certified cosmetic dermatologist with a specialization in facial aesthetics and clinical cosmetics, including Botox, fillers, LASERS, and thread lifts.

The International Board of Cosmetic Dermatology (IBCD) was founded in London by Dr. Arvinder Singh. The board consists of Dermatologists, Plastic Surgeons, Clinical Cosmetologists and Aesthetic Dentistists. The board was established with the goal of giving medical professionals, such as MBBS, Postgraduate doctors, dentists, and Aayush (BHMS, BAMS, BUMS), high-quality education and career opportunities in the fields of Cosmetic Dermatology, Clinical Cosmetology, Medical Aesthetics, and Medical LASERS.

His Academy, Institute of Aesthetic Medicine, Cosmetology, and LASERS (IAMCL), located in India, has been training non-medical students and professionals also who want to pursue careers in cosmetology and aesthetics and become accredited clinical cosmetologists in the vicinity of aesthetic medicine.

Additionally accredited by the UK and registered in the USA, the IAMCL provides course materials in both Hindi and English languages.

Along with this, Dr. Arvinder Singh also established what is thought to be India's first clinical fitness and cosmetology centre in Udaipur and Jaipur, Rajasthan, which has been accredited by the Quality Accreditation Institute (QAI).

Read more:

Dr. Arvinder Singh Awarded As Father Of Cosmetic Dermatology In The International Fame Award - Zee News

Dermatology

The Future of Immunotherapy Targets – Dermatology Times

WavebreakmediaMicro/AdobeStock

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has been a recent breakthrough in the management of both early and late-stage melanoma. With the advent of immunotherapy, the 1-year survival rate for patients with metastatic disease has increased from 25% to 50%.1 ICIs have contributed to improved outcomes of treatment and prognosis of patients with different malignancies and are now served as a standard treatment for advanced melanoma.2

Recent study results revealed that treatment with combined anti-CTLA-4/anti-PD-1 results in median overall survival and a significant durability response, which is superior to that of nivolumab monotherapy and ipilimumab monotherapy.3 Also, the benefits of combined treatment were similar for patients, irrespective of their BRAFV600 mutational and PD-L1 expression status. ICIs provide a significant response in patients with brain metastasis, particularly those who are asymptomatic of malignant infiltration at the time of presentation.4 Study results also revealed that intracranial responses of combined ipilimumab/nivolumab were more than 50% in patients whose metastases have not been treated with brain radiotherapy.5 Another study found that ipilimumab/nivolumab was significantly superior to nivolumab monotherapy with a 5-year survival rate of 51% in patients with asymptomatic disease.6 In the therapeutic field of melanoma, prior immunostimulatory treatments such as interleukin-2 (IL-2) were superseded by ICIs. For high-risk, early-stage melanoma, ipilimumab was found to increase the 3-year recurrence-free rate by more than 10%.6

While surgical excision is the primary treatment for non-melanoma skin cancers (NMSCs), immunotherapy has emerged as a promising treatment option in recent years.7 In the case of NMSCs, ICIs are the most commonly used immunotherapy drugs. These drugs block proteins in cancer cells, preventing the immune system from recognizing and attacking them.8 Clinical trials have shown that ICIs such as pembrolizumab and nivolumab have high response rates and durable responses in patients with advanced NMSCs.9 These drugs have been approved by the US Food and Drug Administration for the treatment of metastatic or locally advanced squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), which cannot be treated with surgery or radiation. Other types of immunotherapies for NMSCs include topical immunomodulators such as imiquimod and ingenol mebutate, which stimulate the immune system to attack cancer cells locally.10 Intralesional immunotherapy, which involves injecting an immune-stimulating substance directly into the tumor, is also being investigated as a potential treatment option. For the treatment of cutaneous SCC (cSCC), pembrolizumab and cemiplimab, two single-agent anti-PD-1 inhibitors, exhibited an overall response rate of 42% and 52% in recurrent/metastatic disease and locally advanced disease, respectively, when used as frontline, first-line treatment for advanced or metastatic cSCC that is not responsive to surgery or radiation.11 Both medications had long-lasting effects with manageable side effects. Merkle cell carcinoma (MCC), like cSCC, is a very immunogenic illness and a promising target for immunotherapy based on ICI. In pre-treated patients with advanced MCC, the JAVELIN Merkel 200 study showed that avelumab resulted in a 33.0% overall response rate and a median duration of response of 40.5 months.12 In comparison to cSCC, BCCs are at least two times more prevalent. The metastatic rate for BCCs is less than 1%, which is substantially lower than that for cSCCs and MCCs. Moreover, cemiplimab has been shown to generate a strong antitumor response in patients with locally advanced BCC.13

Biomarkers of response to immunotherapy in melanoma have been studied to help identify patients most likely to benefit from treatment and develop new therapeutic strategies. Programmed death-ligand 1 (PD-L1) is a protein expressed on the surface of some cancer cells, including melanoma.14 It interacts with the programmed death-1 (PD-1) receptor on T cells, inhibiting their activity and preventing the immune system from attacking cancer cells. Tumors with high levels of PD-L1 expression are more likely to respond to PD-1/PD-L1 checkpoint inhibitors. Tumor mutational burden (TMB) measures the number of mutations present in a tumor's DNA. High TMB is associated with an increased likelihood of response to ICIs, as these mutations may generate new tumor antigens that can be recognized by the immune system.15 TMB is naturally elevated in melanoma and correlates with better responses toimmune checkpoint inhibition depending on the severity of cancer. However, it is not regularly used as a predictor of ICI response. Melanoma responds exceedingly well to ICI; hence, a biomarker of ICI resistance may be more important than a biomarker of response in clinical care. Tumor-infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor microenvironment. Tumors with high levels of TILs are more likely to respond to immunotherapy, as they indicate an ongoing immune response against the tumor.16 The biomarkers of immunotherapy response in melanoma also include immune gene expression profiling and the gut microbiome. Gene expression profiling can be used to assess the activity of immune-related genes within the tumor microenvironment.17 Certain gene signatures have been associated with response to immunotherapy in melanoma. The composition of the gut microbiome has been shown to affect the efficacy of immune checkpoint inhibitors.18 Studies suggest that a more diverse gut microbiome is associated with a better response to immunotherapy.

Biomarkers that can help predict immunotherapy response or resistance in non-melanoma skin cancers include Interferon-gamma (IFN-) signature, Immunoscore, and Circulating tumor DNA (ctDNA). Interferon-gamma (IFN-) signature is a cytokine that plays a vital role in activating the immune system.19 Tumors with a high IFN- signature may be more likely to respond to immunotherapy. The Immunoscore is a measure of the immune cell infiltration and activation within a tumor. A higher Immunoscore may indicate a better response to immunotherapy.20 Circulating tumor DNA (ctDNA) refers to small fragments of DNA that are shed by tumor cells into the bloodstream. The presence of ctDNA may indicate the presence of residual disease, and monitoring ctDNA levels may help predict response to immunotherapy.21

Immunotherapy has revolutionized the treatment of melanoma and non-melanoma skin cancers, and research is ongoing to identify new targets and improve existing therapies. Now considered the gold standard for treating advanced melanoma, immune checkpoint inhibitors (ICIs) have helped improve the treatment and prognosis of patients with a variety of cancers. Median overall survival and a substantial, durable response are achieved with anti-CTLA-4/anti-PD-1 combination therapy. Previous immunostimulatory therapies, such as interleukin-2 (IL-2), have been replaced by immune checkpoint inhibitors in the therapeutic field of melanoma. Patients with advanced NMSCs have shown both a high response rate and long-lasting responses to immune checkpoint inhibitors like pembrolizumab and nivolumab, according to clinical trials. Immunotherapy has been shown to be effective against melanoma, and researchers have been looking at biomarkers of response to better target treatment towards patients suffering from skin cancers. PD-L1 expression, TMB, MSI, TILs, and HPV status have all been identified as potential biomarkers of response to immunotherapy in melanoma and non-melanoma skin cancers. However, additional research is needed to better understand the complex interplay between the tumor microenvironment and the immune system.

References

1. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance.Annual Review of Pathology: Mechanisms of Disease. 2021;16(1):223-249. doi:https://doi.org/10.1146/annurev-pathol-042020-042741

2. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerclinical aspects and relationship with tumour response: a single-centre prospective cohort study.Annals of the Rheumatic Diseases. 2017;77(3):393-398. doi:https://doi.org/10.1136/annrheumdis-2017-212257

3. Hwang JK, Hong J, Yun CO. Oncolytic viruses and immune checkpoint inhibitors: Preclinical developments to clinical trials.International Journal of Molecular Sciences. 2020;21(22):8627. doi:https://doi.org/10.3390/ijms21228627

4. Bence C, Hofman V, Chamorey E, et al. Association of combined PD L1 expression and tumourinfiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.Journal of the European Academy of Dermatology and Venereology. 2019;34(5):984-994. doi:https://doi.org/10.1111/jdv.16016

5. Suda K. Recent Advances in cancer immunotherapy.Biomolecules. 2021;11(2):335. doi:https://doi.org/10.3390/biom11020335

6. Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.The Lancet. 2020;395(10236):1558-1568. doi:https://doi.org/10.1016/s0140-6736(20)30417-7

7. Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Immunotherapy for non-melanoma skin cancer.Current Oncology Reports. 2021;23(11). doi:https://doi.org/10.1007/s11912-021-01120-z

8. Zelin E, Maronese CA, Dri A, et al. Identifying candidates for immunotherapy among patients with non-melanoma skin cancer: A review of the potential predictors of response.Journal of Clinical Medicine. 2022;11(12):3364. doi:https://doi.org/10.3390/jcm11123364

9. Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC).Healthcare. 2017;5(4). doi:https://doi.org/10.3390/healthcare5040082

10. Cives M, Mannavola F, Lospalluti L, et al. Non-melanoma skin cancers: Biological and clinical features.International Journal of Molecular Sciences. 2020;21(15). doi:https://doi.org/10.3390/ijms21155394

11. Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: Updates and new perspectives.Drugs in Context. 2019;8:1-6. doi:https://doi.org/10.7573/dic.212583

12. Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Immunotherapy for non-melanoma skin cancer.Current Oncology Reports. 2021;23(11). doi:https://doi.org/10.1007/s11912-021-01120-z

13. Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.The Lancet Oncology. 2021;22(6):848-857. doi:https://doi.org/10.1016/s1470-2045(21)00126-1

14. Berghoff AS, Ricken G, Widhalm G, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.Histopathology. 2014;66(2):289-299. doi:https://doi.org/10.1111/his.12537

15. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker.Cancer Cell. 2021;39(2):154-173. doi:https://doi.org/10.1016/j.ccell.2020.10.001

16. Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era.Cellular & Molecular Immunology. Published online November 2, 2020:1-18. doi:https://doi.org/10.1038/s41423-020-00565-9

17. Farberg AS, Marson JW, Glazer A, et al. Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: Consensus from the skin cancer prevention working group.Dermatology and Therapy. 2022;12(4):807-823. doi:https://doi.org/10.1007/s13555-022-00709-x

18. Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.Cancer Medicine. 2020;10(3):1141-1154. doi:https://doi.org/10.1002/cam4.3694

19. Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer.Frontiers in Medicine. 2018;5. doi:https://doi.org/10.3389/fmed.2018.00351

20. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature Reviews Cancer. Published online August 4, 2020:1-19. doi:https://doi.org/10.1038/s41568-020-0285-7

21. Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.Annals of Oncology. 2017;28(8):1996-2001. doi:https://doi.org/10.1093/annonc/mdx212

See the original post:

The Future of Immunotherapy Targets - Dermatology Times